Oliver Fetzer
Vermögen: 670 248 $ am 31.05.2026
Vermögen: 670 248 $ am 31.05.2026
Oliver Steffen Fetzer currently works at Viridos, Inc., as Chief Executive Officer & Director from 2014 and Tecan Group AG, as Non-Executive Director from 2011.
Dr. Fetzer also formerly worked at Cerulean Pharma, Inc., as President, Chief Executive Officer & Director from 2009 to 2014, Arena Pharmaceuticals, Inc., as Independent Director from 2017 to 2022, Auxilium Pharmaceuticals LLC, as Independent Director from 2005 to 2015, The Boston Consulting Group, Inc., as Managing Director & Partner from 2000 to 2002, Cubist Pharmaceuticals LLC, as Senior Vice President-Research & Development from 2002 to 2007, and Bayer AG, as Principal.
Dr. Fetzer received his Masters Business Admin degree from Carnegie Mellon University, doctorate degree from The Medical University of South Carolina, and undergraduate degree from College of Charleston.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TECAN GROUP AG 0.03% | 31.12.2024 | 3’370 ( 0.03% ) | 670 248 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TECAN GROUP AG | Direktor/Vorstandsmitglied | 19.04.2011 |
Viridos, Inc.
Viridos, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes genomic-driven solutions and products | Vorstandsvorsitzender | 27.10.2014 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARENA PHARMACEUTICALS | Direktor/Vorstandsmitglied | 11.03.2022 |
| AUXILIUM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 29.01.2015 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Vorstandsvorsitzender | 29.10.2014 |
| CUBIST PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2007 |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Corporate Officer/Principal | 01.01.2002 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer AG
Bayer AG Pharmaceuticals: MajorHealth Technology Provides health care, nutrition and high-tech material services | Health Technology |
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Auxilium Pharmaceuticals LLC
Auxilium Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
Viridos, Inc.
Viridos, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes genomic-driven solutions and products | Commercial Services |
Tecan Group AG
Tecan Group AG Medical SpecialtiesHealth Technology Develops, makes, and distributes robotic sample processors and automatic analyzers for use in labs | Health Technology |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Medical University of South Carolina
Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
College of Charleston
College of Charleston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Design and develops nanopharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen